Drug Trial Radar · NCT00147550
MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
Last checked: Nov 20, 2026Latest source record: Sep 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
79
Actual
Start
Feb 2004
Primary completion
May 2007
Study completion Jul 2013
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 7, 2005
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells. PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of this study is to study the effectiveness of PD-325901 in patients with colon cancer, breast cancer, and melanoma. PD-325901 will be given by mouth as a pill twice a day, CT scans will be done and biopsies will be taken of a tumor before and once during treatment to measure the effects of the drug. Blood samples will be taken to measure the amount of drug in the blood.
Conditions
- Melanoma
- Colonic Neoplasms
- Breast Neoplasms
Interventions
PD-0325901Drug
Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate, Safety.Time frame: duration of trial
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
La Jolla, California
Pfizer Investigational Site
La Mesa, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Santa Monica, California
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
Detroit, Michigan
Pfizer Investigational Site
Rochester, Minnesota
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
Cleveland, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.